Aadi Bioscience (NASDAQ:AADI) Posts Earnings Results, Misses Expectations By $0.36 EPS

Aadi Bioscience (NASDAQ:AADI) posted its quarterly earnings data on Tuesday. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.36), Zacks reports. Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%.

Aadi Bioscience Price Performance

Shares of AADI stock traded down $0.04 during trading hours on Tuesday, reaching $2.06. 49,245 shares of the stock were exchanged, compared to its average volume of 244,689. The business’s fifty day moving average is $2.73 and its two-hundred day moving average is $2.40. The firm has a market capitalization of $50.80 million, a P/E ratio of -0.90 and a beta of 0.68. Aadi Bioscience has a 12-month low of $1.21 and a 12-month high of $3.81.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.